UBS Group Reiterates “Buy” Rating for Novo Nordisk A/S (NVO)

Novo Nordisk A/S (NYSE:NVO)‘s stock had its “buy” rating restated by research analysts at UBS Group in a report issued on Sunday, www.tipranks.com reports.

A number of other analysts also recently issued reports on NVO. Zacks Investment Research raised Novo Nordisk A/S from a “sell” rating to a “hold” rating in a research report on Tuesday, November 20th. Kepler Capital Markets reaffirmed a “hold” rating on shares of Novo Nordisk A/S in a research report on Thursday, November 29th. HSBC reaffirmed a “sell” rating on shares of Novo Nordisk A/S in a research report on Monday, November 26th. Pareto Securities raised Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research report on Monday, November 26th. Finally, ValuEngine raised Novo Nordisk A/S from a “sell” rating to a “hold” rating in a research report on Saturday, October 27th. Two investment analysts have rated the stock with a sell rating, four have given a hold rating and six have assigned a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average target price of $64.00.

Shares of Novo Nordisk A/S stock opened at $46.04 on Friday. The stock has a market capitalization of $113.92 billion, a PE ratio of 19.68, a PEG ratio of 2.46 and a beta of 0.75. Novo Nordisk A/S has a one year low of $41.23 and a one year high of $58.37.

Novo Nordisk A/S (NYSE:NVO) last released its earnings results on Thursday, November 1st. The company reported $0.58 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.58. The business had revenue of $4.31 billion for the quarter, compared to the consensus estimate of $4.11 billion. Novo Nordisk A/S had a return on equity of 81.50% and a net margin of 34.94%. On average, sell-side analysts anticipate that Novo Nordisk A/S will post 2.45 EPS for the current year.

Several large investors have recently added to or reduced their stakes in NVO. Renaissance Technologies LLC increased its position in Novo Nordisk A/S by 12.0% during the second quarter. Renaissance Technologies LLC now owns 19,142,300 shares of the company’s stock worth $882,843,000 after buying an additional 2,051,000 shares during the last quarter. Alliancebernstein L.P. acquired a new position in Novo Nordisk A/S during the third quarter worth approximately $70,602,000. Envestnet Asset Management Inc. increased its position in Novo Nordisk A/S by 943.0% during the second quarter. Envestnet Asset Management Inc. now owns 625,349 shares of the company’s stock worth $28,841,000 after buying an additional 565,395 shares during the last quarter. Loomis Sayles & Co. L P increased its position in Novo Nordisk A/S by 2.1% during the third quarter. Loomis Sayles & Co. L P now owns 21,742,529 shares of the company’s stock worth $1,024,943,000 after buying an additional 457,466 shares during the last quarter. Finally, First Trust Advisors LP increased its position in Novo Nordisk A/S by 4,736.6% during the second quarter. First Trust Advisors LP now owns 466,631 shares of the company’s stock worth $21,521,000 after buying an additional 456,983 shares during the last quarter. 6.84% of the stock is currently owned by institutional investors and hedge funds.

About Novo Nordisk A/S

Novo Nordisk A/S, a healthcare company, engages in the discovery, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes Care and Obesity, and Biopharmaceuticals. The Diabetes Care and Obesity segment provides insulins, GLP-1 and related delivery systems, and oral anti-diabetic drugs and obesity.

Recommended Story: Purposes and Functions of the Federal Reserve

Analyst Recommendations for Novo Nordisk A/S (NYSE:NVO)

Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit